HC Wainwright Reaffirms Neutral Rating for Sutro Biopharma (NASDAQ:STRO)

HC Wainwright reiterated their neutral rating on shares of Sutro Biopharma (NASDAQ:STRO) in a report published on Monday morning, Marketbeat Ratings reports. They currently have a $2.00 target price on the stock, down from their previous target price of $12.00.

Several other equities research analysts have also commented on STRO. Wedbush lowered Sutro Biopharma from an “outperform” rating to a “neutral” rating and cut their target price for the company from $8.00 to $2.00 in a research report on Friday. Bank of America lowered Sutro Biopharma from a “buy” rating to an “underperform” rating and cut their target price for the company from $11.00 to $1.00 in a research report on Friday. Wells Fargo & Company cut their target price on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. Citizens Jmp lowered Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research report on Friday. Finally, JMP Securities reiterated a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $7.75.

Sutro Biopharma Trading Up 15.1 %

NASDAQ STRO opened at $0.93 on Monday. The business’s 50-day moving average price is $1.73 and its two-hundred day moving average price is $2.70. Sutro Biopharma has a 12 month low of $0.76 and a 12 month high of $6.13. The firm has a market capitalization of $76.88 million, a PE ratio of -0.58 and a beta of 1.22.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings results on Thursday, March 13th. The company reported ($2.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($2.10). Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. The company had revenue of $14.00 million during the quarter, compared to the consensus estimate of $10.44 million. During the same quarter last year, the firm posted ($1.78) EPS. As a group, analysts forecast that Sutro Biopharma will post -2.92 earnings per share for the current fiscal year.

Institutional Trading of Sutro Biopharma

Several institutional investors and hedge funds have recently modified their holdings of STRO. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Sutro Biopharma in the fourth quarter worth approximately $26,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Sutro Biopharma in the fourth quarter worth approximately $32,000. Vontobel Holding Ltd. raised its stake in shares of Sutro Biopharma by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $46,000 after purchasing an additional 10,000 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Sutro Biopharma by 74.3% in the fourth quarter. ProShare Advisors LLC now owns 26,961 shares of the company’s stock worth $50,000 after purchasing an additional 11,494 shares during the last quarter. Finally, Velan Capital Investment Management LP purchased a new stake in shares of Sutro Biopharma in the fourth quarter worth approximately $55,000. 96.99% of the stock is owned by hedge funds and other institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.